Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | WRN | Q14191 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | WNT3 | P56703 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12092098 | 0.90 | LMNA (0.47) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL26712776 | 0.86 | MAPT (0.41) | LMNAMAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL19749038 | 0.86 | PKM (0.42) | LMNAKMT2ATP53 | |
| SCHEMBL12377426 | 0.85 | CTH (0.35) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL18294901 | 0.84 | LMNA (0.37) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL18294898 | 0.84 | LMNA (0.37) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL20434503 | 0.84 | EPHX2 (0.40) | LMNAKMT2AMEN1SMN1; SMN2HPGD | |
| SCHEMBL14519321 | 0.83 | LMNA (0.38) | LMNAMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL18294905 | 0.83 | ALDH1A1 (0.43) | LMNAKMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL16483737 | 0.82 | SMN1; SMN2 (0.33) | LMNAKMT2AMEN1PIM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339997-A1 | CLASS OF PLATINUM COMPOUNDS FOR TREATING CANCER, AND METHOD FOR PREPARATION THEREOF | SHANGHAI HAIJU BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| WO-2022052014-A1 | CLASS OF PLATINUM COMPOUNDS FOR TREATING CANCER, AND METHOD FOR PREPARATION THEREOF | 上海海聚生物科技有限公司 | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339997-A1 | CLASS OF PLATINUM COMPOUNDS FOR TREATING CANCER, AND METHOD FOR PREPARATION THEREOF | TP53, ERCC4, SLC19A1 | LMNA 3986/4885MAPT 4344/4885KMT2A 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.